BioMedInvest-II LP Joins Humedics Series C Financing
News Dec 30, 2014
Humedics GmbH has announced that BioMedInvest-II LP complementary joins the Series C financing round now totaling more than 7 million Euro. Humedics’ business model, products and company development has attracted another international investor.
Switzerland-based BioMedPartners with their BioMedInvest-II LP fund joins as co-lead the newly formed syndicate of investors in follow up of the recent announcement of the Humedics’ Series C financing round that was led by two international investors, Vesalius Biocapital Partners and Seventure Partners.
BioMedInvest-II LP invests in innovative early- to mid-stage companies that have the potential to achieve exceptional growth driven by novel technologies with unique advantages over current products. Humedics therefore perfectly fits into this portfolio with their medical device, the diagnostic drug and the clinically demonstrated significant added value of the LiMAx test in liver disease and liver surgery. BioMedInvest-II LP will be represented on the Humedics Board by Dr. Karsten Fischer.
The raised capital will be used for the European market entry of Humedics’ proprietary LiMAx test and the corresponding FLIP diagnostic device. This breath test based diagnostic system represents a revolution in functional liver diagnostics by enabling clinicians to quantitatively determine the individual liver function capacity for a patient within minutes. It allows for better risk assessment in liver surgery and thus, superior surgery planning as well as selecting treatment strategies optimally adapted to the individual patients liver status. The LiMAx test provides certainty for the physician, safety for the patient and leads to cost reduction for the hospital.
Erwin de Buijzer, Managing Director of Humedics GmbH and private co-investor in the financing round, states: “2014 has been a highly successful year for us. The closing of the series C financing round provides the financial basis for preparing a successful launch of our LiMAx test. Feedback from customers is extremely positive and confirms the dramatic reduction of mortality after liver surgery in the centers that use the LiMAx test. We are very pleased with the support from all investors, which enables us to commercialize one of the major innovations in liver function testing.”
In a small study of patients referred to the Johns Hopkins Early Psychosis Intervention Clinic (EPIC), researchers report that about half the people referred to the clinic with a schizophrenia diagnosis didn’t actually have schizophrenia. People who reported hearing voices or having anxiety were the ones more likely to be misdiagnosed.